Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
— Hippocrates
Glioblastoma multiforme (GBM) is a highly aggressive and heterogeneous brain cancer. Because of its complex nature, traditional treatments often fail to provide long-term survival. However, researchers are now focusing on targeted GBM therapy to improve clinical outcomes. By utilizing receptors overexpressed on the surface of tumor cells, scientists can deliver medication more precisely.
One major focus of this research involves receptors like interleukin-13 receptor alpha 2 (IL-13Rα2) and the transferrin receptor (TfR). These biomarkers allow for specific binding of drug-loaded carriers. Consequently, this approach reduces the exposure of healthy brain tissue to toxic chemotherapy. Furthermore, integrins and receptor tyrosine kinases (RTKs) serve as additional vital targets for these innovative platforms.
Modern nanotechnology plays a critical role in these advancements. Clinicians are exploring nanoparticles such as liposomes and gold nanostructures. These carriers are functionalized with specialized ligands like RGD peptides. These ligands act as a GPS, guiding drugs like temozolomide and gefitinib directly to the tumor. As a result, early-phase clinical trials are already showing promising safety and efficacy profiles.
Despite these successes, some challenges remain. For example, nanoparticle-associated cytotoxicity and off-target effects can limit clinical translation. Therefore, future research must prioritize the development of biodegradable and biocompatible nanomaterials. Additionally, exploring underexplored receptors like periostin (POSTN) could reveal new pathways for overcoming therapeutic resistance.
Commonly targeted receptors include IL-13Rα2, TfR, and integrins. These are highly expressed on tumor cells compared to normal brain tissue, allowing for selective drug delivery.
The main hurdles include crossing the blood-brain barrier effectively and minimizing nanoparticle-associated toxicity. Researchers are working on biocompatible designs to solve these issues.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Hadri SH et al. Exploring the potential of multiple receptors overexpressed on glioblastoma cells as biomarkers for the targeted therapy; a review. Ther Deliv. 2026 Jun 11. doi: 10.1080/20415990.2026.2682697. PMID: 42273826.
Rahman MA et al. Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating Opportunities. Cancers (Basel). 2025 Feb 19;17(4):701. doi: 10.3390/cancers17040701. PMID: 40002294.
Link will be sent via SMS to your number.
Glioblastoma multiforme remains a major clinical challenge. However, new research into targeted GBM therapy using specific receptors and nanoparticle-based delivery systems offers a path toward more effective and less toxic treatments. This review highlights recent progress and future opportunities.
Today
A landmark study published in Cell Genomics reveals that overcrowding, poor sanitation, and socioeconomic inequality are primary drivers of global antimicrobial resistance. Reducing antibiotic consumption alone will not suffice, highlighting the urgent need for structural public health reforms by 2050.
Today
A new study reveals that hyperactivating the Hedgehog pathway with Smoothened Agonist (SAG) causes significant craniofacial development defects in mice. By disrupting cell proliferation and cell-cycle progression during a critical window, SAG exposure leads to cleft lip and other cranial abnormalities.
Today
A study of 221 patients reveals that IVUS guidance during intracoronary brachytherapy for in-stent restenosis significantly reduces target lesion revascularization (21% vs 37%) and major adverse cardiovascular events, ensuring better long-term procedural success and improved patient safety.
Today
Despite their expertise in ergonomics, physiotherapists face high rates of work-related musculoskeletal disorders. New research identifies low back pain and repetitive tasks as leading issues, with female practitioners showing significantly higher risk profiles compared to their male counterparts.
Today
A comprehensive pathological study reveals that medial and intimal calcification follow distinct, inverse distribution patterns in the lower extremities, with medial calcification significantly linked to chronic kidney disease.
Today